Home » Stocks » VIR

Vir Biotechnology, Inc. (VIR)

Stock Price: $31.44 USD -2.39 (-7.06%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
After-hours: $31.20 -0.24 (-0.76%) Oct 30, 7:59 PM

Stock Price Chart

Key Info

Market Cap 3.99B
Revenue (ttm) 75.09M
Net Income (ttm) -220.49M
Shares Out 127.05M
EPS (ttm) -14.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $31.44
Previous Close $33.83
Change ($) -2.39
Change (%) -7.06%
Day's Open 33.51
Day's Range 30.35 - 33.51
Day's Volume 981,581
52-Week Range 11.65 - 75.00

More Stats

Market Cap 3.99B
Enterprise Value 3.44B
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 127.05M
Float 47.17M
EPS (basic) 0.19
EPS (diluted) -14.64
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 7.24M
Short Ratio 6.05
Short % of Float 15.34%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 53.20
PB Ratio 7.46
Revenue 75.09M
Operating Income -212.40M
Net Income -220.49M
Free Cash Flow n/a
Net Cash 550.64M
Net Cash / Share 4.33
Gross Margin -179.76%
Operating Margin -282.86%
Profit Margin -293.60%
FCF Margin n/a
ROA -22.96%
ROE -45.69%
ROIC -97.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (8)

Buy 5
Overweight 0
Hold 2
Underweight 1
Sell 0

Analyst Consensus: Buy

Price Target

(72.20% upside)
Current: $31.44
Target: 54.14
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-24.16%293.94%-
Gross Profit8.0910.672.71
Operating Income-178-119-81.50
Net Income-175-116-69.85
Shares Outstanding30.357.672.15
Earnings Per Share-5.76-15.12-32.45
Operating Cash Flow-130-94.10-66.38
Capital Expenditures-8.94-8.17-2.74
Free Cash Flow-139-102-69.12
Cash & Equivalents390109188
Net Cash / Debt390109188
Book Value424-179-68.92
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Vir Biotechnology, Inc.
Country United States
Employees 253
CEO George A. Scangos

Stock Information

Ticker Symbol VIR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VIR
IPO Date October 11, 2019


Vir Biotechnology, a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.